- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S3380
| Related Targets | PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX |
|---|---|
| Other Antiviral Products | Moroxydine HCl Aloperine GS-441524 Oleanolic Acid NGI-1 Lapachol Saikosaponin B2 Harringtonine U18666A Carrageenan |
|
In vitro |
DMSO
: 75 mg/mL
(199.29 mM)
Ethanol : 18 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 376.33 | Formula | C19H15F3N2O3
|
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 869572-92-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | SIGA-246, ST-246, TPOXX | Smiles | FC(F)(F)C1=CC=C(C=C1)C(=O)NN2C(=O)C3C4C=CC(C5CC45)C3C2=O | ||
| Targets/IC50/Ki |
p37 protein ortholog
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00907803 | Completed | Orthopoxviral Disease |
SIGA Technologies|National Institutes of Health (NIH) |
June 2009 | Phase 2 |
| NCT00728689 | Completed | Orthopoxviral Disease|Smallpox|Monkey Pox |
SIGA Technologies|National Institutes of Health (NIH) |
August 2008 | Phase 1 |
| NCT00431951 | Completed | Healthy |
SIGA Technologies|National Institute of Allergy and Infectious Diseases (NIAID) |
February 2007 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.